Anthera Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Cash used in financing activities reached the amount of $0 last year.
Cash Flow
| 2012 | -73.63M | -3.78M | 31.25M |
|---|---|---|---|
| 2013 | -31.91M | -4.68M | 43.11M |
| 2014 | -25.60M | 10M | -7.70M |
| 2015 | -30.90M | -80K | 75.29M |
| 2016 | -48.91M | -766K | 23.57M |
| 2017 | -36.9M | 0 | 18.25M |
| 2019 | 0 | 0 | 0 |
| 2020 | 0 | 0 | 0 |
| 2021 | 0 | 0 | 0 |
| 2022 | 0 | 0 | 0 |
ANTH Cash Flow Statement (2012 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 0 | 0 | 0 | 0 | 20.84M | 46.95M | 2.63M | 25.94M | 19.43M | 65.62M |
Operating activities | ||||||||||
Net income | 0 | 0 | 0 | 0 | -26.87M | -55.52M | -35.22M | -29.60M | -30.86M | -59.39M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 281K | 266K | 285K | 344K | 353K | 331K |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 4.37M | 6.73M | 3.54M | 2.17M | 3.14M | 960K |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 4.37M | 6.73M | 3.54M | 2.17M | 3.14M | 960K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 326K | -326K | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 1.63M | 350K | 0 | 0 | 0 |
Accounts payable | 0 | 0 | 0 | 0 | -2.95M | -477K | 3.02M | -1.21M | -1.83M | -12.22M |
Cash generated by operating activities | 0 | 0 | 0 | 0 | -36.9M | -48.91M | -30.90M | -25.60M | -31.91M | -73.63M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -10.67M |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | -766K | -80K | 0 | -15K | -207K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | -766K | -80K | 10M | -4.68M | -3.78M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 18.25M | 6.73M | 75.29M | 10.38M | 45.78M | 35.76M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -18.09M | -22.43M | -4.46M |
Cash used in financing activities | 0 | 0 | 0 | 0 | 18.25M | 23.57M | 75.29M | -7.70M | 43.11M | 31.25M |
Net Change In Cash | 0 | 0 | 0 | 0 | -18.64M | -26.10M | 44.31M | -23.30M | 6.51M | -46.19M |
Cash at end of period | 0 | 0 | 0 | 0 | 2.19M | 20.84M | 46.95M | 2.63M | 25.94M | 19.43M |